Eisai Corporation of North America today announced that the U.S. FDA has approved LUSEDRA (fospropofol disodium) Injection, an intravenous sedative-hypnotic agent for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.
The details can be read here.
No comments:
Post a Comment